Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
RUTIN | CHEMICAL INFORMATION | USP41–NF36 | 4841 | 29-Mar-2019 | 1-Apr-2019 | NA | NA | Change 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one-3-yl 6-O-α-L-rhamnopyranosyl-β-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol… Read More |
ZONISAMIDE | IMPURITIES/Organic Impurities | USP42–NF37 | 4675 | 28-Jun-2019 | 1-Jul-2019 | NA | NA | In Analysis: Change CU = concentration of zonisamide related compound A in the Sample solution (mg/mL) to: CU = concentration of zonisamide in the Sample solution (mg/mL) |
25% TETRABUTYLAMMONIUM HYDROXIDE TS | REAGENTS AND REFERENCE TABLES/Solutions | Second Supplement to USP42–NF37 | 9336 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Transfer about 34.82 g to: Transfer about 77.1 g |
SUCROSE PALMITATE | IMPURITIES/Inorganic Impurities | USP43–NF38 | 6078 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Fats and Fixed Oils, Acid Value <401>: Change NMT 6.0%, to: NMT 6.0, |
<1079> RISKS AND MITIGATION STRATEGIES FOR THE STORAGE AND TRANSPORTATION OF FINISHED DRUG PRODUCTS | 4. RISK MITIGATION CATEGORIES AS QMS ELEMENTS | Second Supplement to USP43–NF38 | Online | 29-Jan-2021 | 1-Feb-2021 | NA | NA | In 4.1 Documentation and Procedures/4.1.3 Labels: Change The use of symbols that are recognized by international organizations is strongly recommended. to: The use of symbols that are recognized by international organizations is strongly… Read More |
VORICONAZOLE | IDENTIFICATION/A. | USP43–NF38 | 4643 | 25-Sep-2020 | 1-Oct-2020 | NA | NA | Change Infrared Absorption 〈197K〉 to: Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197K |
BENAZEPRIL HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/USP References Standards <11> | USP43–NF38 | Online | 25-Jun-2021 | 1-Jul-2021 | NA | NA | In USP Benazepril Related Compound B RS: Change (3S)-3-[[(1R)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid, monohydrochloride; Also known as 2-[(SR)-3-{[(RS)-1-… Read More |
EXTENDED PHENYTOIN SODIUM CAPSULES | IMPURITIES/Organic Impurities | Revision Bulletin (Official March 01, 2021) | Online | 31-Dec-2021 | 1-Jan-2022 | NA | NA | In both Calculations in Analysis: Change CU = nominal concentration of phenytoin in the Sample solution (µg/mL) to: CU = nominal concentration of phenytoin sodium in the Sample solution (µg/mL) |
DOXYCYCLINE FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
NALOXONE HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 28-Oct-2022 | 1-Dec-2022 | NA | NA | In Limit of Naloxone Related Compound D: Delete Sensitivity solution: 1.25 µg/mL of USP Naloxone Related Compound D RS in 0.1 N hydrochloric acid AND In System suitability/Samples: Delete Sensitivity solution,… Read More |
ISOFLURANE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Analysis: Change Result = (rU/rS) × CS × (1/F) to: Result = (rU/rS) × CF × (1/F) AND Change CS… Read More |
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 29-Sep-2023 | 1-Oct-2023 | NA | NA | In Dissolution 〈711〉/Test 8/Tolerances: Change The percentage of the labeled amount of valproic acid (C8H16O2) dissolved at the times specified conform to Dissolution <711>, Acceptance… Read More |
BENZETHONIUM CHLORIDE | IMPURITIES/Organic Impurities/Acceptance criteria | First Supplement to USP41–NF36 | 8297 | 25-Jan-2019 | 1-Feb-2019 | NA | NA | In Total impurities: Change 1.0% to: NMT 1.0% |
DIDANOSINE | IMPURITIES/Related Compounds | USP42–NF37 | 1336 | 31-May-2019 | 1-Jun-2019 | NA | NA | In System suitability solution: Change 0.5 mg/mL of of didanosine from USP Didanosine System Suitability Mixture RS in Diluent to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in Diluent |
MECLOFENAMATE SODIUM | CHEMICAL INFORMATION | USP42–NF37 | 2706 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W. |
LEUCOVORIN CALCIUM FOR INJECTION | ASSAY/Procedure/Chromatographic system | USP43–NF38 | 2569 | 24-Apr-2020 | 1-May-2020 | NA | NA | Delete Run time: 2 times the retention time of the leucovorin peak |
<1671> THE APPLICATION OF MOISTURE VAPOR TRANSMISSION RATES FOR SOLID ORAL DOSAGE FORMS IN PLASTIC PACKAGING SYSTEMS | EQUIVALENCY AND APPLICATION OF MVTR DETERMINATION METHOD | Second Supplement to USP43–NF38 | Online | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In Application/paragraph 3: Change ≤0.8/day/tablet to: ≤0.8 mg/day/tablet |
PROPYLENE CARBONATE | ASSAY/Procedure/Titrimetric system | USP43–NF38 | 5986 | 26-Jun-2020 | 1-Jul-2020 | NA | NA | In Mode: Change Direct titration to: Residual titration |
AZITHROMYCIN FOR ORAL SUSPENSION | ASSAY/Procedure | USPNF 2021 ISSUE 1 | Online | 30-Apr-2021 | 1-May-2021 | NA | NA | In Solution A: Change orthophosphoric acid to: phosphoric acid |
RIVASTIGMINE TARTRATE | IMPURITIES | USPNF Online | Online | 26-Apr-2024 | 1-May-2024 | NA | NA | In Organic Impurities/Procedure 1/Impurity Table 1/footnote d: Change 3-Nitrophenyl ethyl(methyl)carbamate. to: 4-Nitrophenyl ethyl(methyl)carbamate. |
<1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-GENERAL | 2. INTRODUCTION | USPNF 2021 ISSUE 1 | Online | 24-Sep-2021 | 1-Oct-2021 | NA | NA | In paragraph five: Change Determination of Zeta Potential by Electrophoretic Light Scattering 〈432〉1 to: Determination of Zeta Potential by Electrophoretic Light Scattering 〈432〉 AND In footnote 1: Change This… Read More |
ONDANSETRON TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 25-Mar-2022 | 1-Apr-2022 | NA | NA | Change USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H… Read More |
DEXMEDETOMIDINE HYDROCHLORIDE | CHEMICAL INFORMATION | USP41–NF36 | Online | 22-Feb-2019 | 1-Mar-2019 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction |
LEVOCARNITINE | IMPURITIES/Enantiomeric Purity | USP42–NF37 | 2541 | 31-May-2019 | 1-Jun-2019 | NA | NA | In the second equation in Analysis: Change Result = (RL − PB)/(PA − PB) to: Result = (RL − PB)/(PA… Read More |
DESFLURANE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane. |
RALTEGRAVIR TABLETS | ASSAY/Procedure | USP43–NF38 | 3834 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Analysis: Change Mr1 = molecular weight of raltegravir, 444.44 to: Mr1 = molecular weight of raltegravir, 444.42 |
MIRTAZAPINE TABLETS | ADDITIONAL REQUIREMENTS | USP43–NF38 | 2978 | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In USP Reference Standards <11>/USP Mirtazapine Resolution Mixture RS: Change This resolution mixture contains approximately 0.1% w/w each of the following: Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c… Read More |
FUROSEMIDE TABLETS | Assay | USP43–NF38 | 2056 | 31-Jul-2020 | 1-Aug-2020 | NA | NA | Change: Mobile phase, Diluting solution, System suitability solution, and Chromatographic system—Prepare as directed in the test for Related compounds under Furosemide. to: Mobile phase—Prepare a… Read More |
CARBOMER COPOLYMER | IMPURITIES | USPNF 2021 ISSUE 1 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | In Limit of Ethyl Acetate and Cyclohexane/Analysis: Change Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C, and Sample solution to: Samples: Standard solution A, Standard… Read More |
DOXAZOSIN MESYLATE | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In Table 2: Change Doxazosin related compound Dg 0.83, 196.16, 196.16, 0.25 to: Doxazosin related compound Dg 0.83, 180.16, 180.16, 0.25 |
MUPIROCIN CALCIUM | CHEMICAL INFORMATION | USPNF Online | Online | 29-Apr-2022 | 1-May-2022 | NA | NA | Change 1075.34 to: 1075.35 |
LANSOPRAZOLE DELAYED-RELEASE CAPSULES | IMPURITIES/Organic Impurities | USPNF Online | Online | 30-Sep-2022 | 1-Oct-2022 | NA | NA | Delete Blank: Methanol and Diluent (1:9) |
ERYTHROMYCIN DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution 〈711〉 | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | In Test 1: Change Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see Reagents, Indicators, and Solutions—Buffer Solutions) to: Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see Reagents,… Read More |
DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION | Assay | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Chromatographic system and Procedure: Change C is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the Standard preparation; to: C is the concentration, in mg per mL… Read More |
METOLAZONE | IMPURITIES | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In Organic Impurities/Chromatographic system/Column: Change 4.6-mm × 25-cm; 5-µm packing 1 to: 4.6-mm × 25-cm; 5-µm packing L1 |
LEVALBUTEROL INHALATION SOLUTION | IMPURITIES/Organic Impurities | USP42–NF37 | 2520 | 26-Apr-2019 | 1-May-2019 | NA | NA | In Row 3 of Table 3: Change Levalbuterol — — — to: Levalbuterol 1.0 — — |
BUSPIRONE HYDROCHLORIDE TABLETS | IDENTIFICATION/B. | USP42–NF37 | 621 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | Change relative retention time to: retention time |
ALFADEX | CHEMICAL INFORMATION | USP42–NF37 | 5561 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | Change 972.84 to: 972.85 |
POWDERED BILBERRY EXTRACT | COMPOSITION | USP43–NF38 | 4813 | 29-May-2020 | 1-Jun-2020 | NA | NA | In Content of Anthocyanosides and Anthocyanidins/System suitability/Resolution: Change petunidin-3-O-arabinose to: petunidin-3-O-arabinoside |
AMITRIPTYLINE HYDROCHLORIDE | ASSAY/Procedure | USP43–NF38 | 261 | 26-Feb-2021 | 1-Mar-2021 | NA | NA | In System suitability solution: Change 0.5 µg/mL of USP Amitriptyline Related Compound A RS, 1 µg/mL of USP Amitriptyline Hydrochloride RS, and 1.5 µg/mL each of USP Amitriptyline Related Compound B RS, USP Cyclobenzaprine Hydrochloride RS, and USP… Read More |
<661> PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION | POLYETHYLENE TEREPHTHALATE BOTTLES AND POLYETHYLENE TEREPHTHALATE G CONTAINERS | First Supplement to USP43–NF38 | Online | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Extracting media: Change 50 percent alcohol: Dilute 125 mL of alcohol with water to 238 mL, and mix. 25 percent alcohol: Dilute 125 mL of 50 percent alcohol… Read More |
QUAZEPAM | ADDITIONAL REQUIREMENTS/USP Reference standards <11> | USP43–NF38 | 3790 | 30-Jul-2021 | 1-Aug-2021 | NA | NA | In USP Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one. |
NICARDIPINE HYDROCHLORIDE INJECTION | DEFINITION | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | Change NTL 90.0% to: NLT 90.0% |
AMMONIUM GLYCYRRHIZATE | ASSAY/Content of Ammonium 18α- and 18β-Glycyrrhizate | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Analysis: Change MW(Salt) = molecular weight of ammonium glycyrrhizate, 840.08 g/mol MW(Acid) = molecular weight of glycyrrhizic acid, 821.59 g/mol to: MW(Salt) = molecular weight of… Read More |
MAFENIDE ACETATE FOR TOPICAL SOLUTION | IMPURITIES/Organic Impurities | USPNF Online | Online | 16-Dec-2022 | 1-Jan-2023 | NA | NA | In System suitability: Change Samples: System suitability solution, Standard solution A, and Standard solution B to: Samples: System suitability solution and Standard solution A AND … Read More |
OSELTAMIVIR PHOSPHATE | IMPURITIES/Organic Impurities/Procedure 3: Limit Of Tributyl Phosphine Oxide | USPNF Online | Online | 26-May-2023 | 1-Jun-2023 | NA | NA | In System suitability/Suitability requirements/Relative standard deviation: Change NMT 10.0% for the tributyl phosphine oxide and osteltamivir phosphate peaks to: NMT 10.0% for the tributyl phosphine oxide and oseltamivir phosphate… Read More |
<631> COLOR AND ACHROMICITY | METHOD II: INSTRUMENTAL (QUANTITATIVE) ASSESSMENT OF COLOR AND COLOR MATCHES | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Table 5: Change Sum 98.809 100.000 107.307 White point 98.811 100.000 107.304 to: Sum 94.809 100.000 107.307 White point 94.811 100.000 107.304 |
MESNA | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP41–NF36 | 8904 | 22-Feb-2019 | 1-Mar-2019 | NA | NA | In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. C4H8O4S2 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. C4… Read More |
REAGENTS AND REFERENCE TABLES | SOLUTIONS/0.01 M Edetate Disodium VS | USP42–NF37 | 6179 | 31-May-2019 | 1-Jun-2019 | NA | NA | In Standardization: Change previously dried at 100° to: previously dried at 110° |
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE | INTRODUCTION | USP42–NF37 | 8021 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU |